Images

Representative figures of Fluorodeoxyglucose PET ([18F]FDG-PET) images in a control subject and a patient with advanced Alzheimer’s Disease (AD).

Examples of amyloid-negative and amyloid-positive positron emission tomography (PET) scans. In this figure, the amyloid-PET ligand [18F]AZD4694 is shown.

Schematic representation of a healthy brain and Alzheimer’s disease (AD) brain. Compared to the healthy brain, the brain with AD, as the disease progresses, features an atrophied cerebral cortex, shrinkage of the hippocampus, and enlargement of the ventricles.

This image shows the four stages of biomarker discovery from Step 1: Identifying Targets to Step 4: Ensuring Clinical Benefit. 

This image shows exemplars of biomarkers of Schizophrenia. A) Resting state Functional MRI, B) SCI (Striatal Connectivity Index), and C) FSA (Functional Striatal Abnormalities).

The Norwegian HUNT survey found a strong association between chronic headache and musculoskeletal symptoms and joint pain.